Want to join the conversation?
Drugmaker $VRTX reported a narrower 2Q16 loss driven by product revenue from cystic fibrosis treating drugs Orkambi and Kalydeco. Net loss narrowed to $64.53MM or $0.26 per share from $188.85MM or $0.78 per share last year. Revenue grew to $431.61MM from $166.08MM. Non-GAAP EPS was $0.24 compared to loss of $0.54 per share a year ago.
$DB is going to cut off services for about 3,400 clients in equities trading.
$F stock slid more than 2% after the company issued two safety recalls involving more than 650,000 Ford Fusion and Lincoln MKZ model cars.
The new CEO of $SBUX, Kevin Johnson, has some pretty large shoes to fill but there are many who have good faith in his ability to do so.
$TSLA opening a showroom in Michigan. A bold move !!